Small Trial of Alendronate Impact on the Reservoir of HIV

Summary

This clinical trial is designed to test the effects of alendronate (ALN) on people living with HIV who are already receiving antiretroviral therapy (ART). Participants are randomly assigned in a 2:1 ratio to either receive alendronate or a placebo, and neither the participants nor the researchers know who is receiving the actual treatment. The goal is to see if alendronate can reduce the size and activity of the HIV-1 reservoir in these individuals.

Timeline

Start

2026-06-27

Primary completion

2027-03-26

Completion

2027-05-21

Drugs

Indications